Research programme: gastro-oesophageal reflux therapy - Nycomed

Drug Profile

Research programme: gastro-oesophageal reflux therapy - Nycomed

Alternative Names: P-CABs - Nycomed

Latest Information Update: 11 Apr 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nycomed
  • Developer Takeda Pharmaceuticals International GmbH
  • Class Imidazoles; Pyridines; Small molecules
  • Mechanism of Action Potassium-competitive acid blockers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Gastro-oesophageal reflux

Most Recent Events

  • 01 Apr 2012 Discontinued - Preclinical for Gastro-oesophageal reflux in Europe (PO)
  • 30 Sep 2011 Nycomed has been acquired by Takeda
  • 02 Apr 2008 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top